Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

Mitchell Gross1*, Celestia Higano2, Allan Pantuck3, Olga Castellanos1, Erica Green1, Koo Nguyen1 and David B Agus1

Author Affiliations

1 Louis Warschaw Prostate Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

2 Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA

3 Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA

For all author emails, please log on.

BMC Cancer 2007, 7:142  doi:10.1186/1471-2407-7-142

Published: 27 July 2007

Abstract

Background

Docetaxel is the standard first-line agent for the treatment of androgen-independent prostate cancer (AIPC). The combination of docetaxel with molecularly targeted therapies may offer the potential to increase the efficacy and decrease the toxicity of cytotoxic chemotherapy for prostate cancer. Previous studies demonstrate activation of the human epidermal growth factor receptor (EGFR) in prostate cancer. Erlotinib is a specific inhibitor of the tyrosine-kinase activity of EGFR. The goal of this study is to determine the anti-cancer activity docetaxel combined with erlotinib for the treatment of elderly subjects with AIPC.

Methods

This is a multi-institutional Phase II study in patients with histologically confirmed adenocarcinoma of the prostate and age ≥ 65 years. Patients were requred to have progressive disease despite androgen-deprivation therapy as determined by: (1) measurable lesions on cross-sectional imaging; (2) metastatic disease by radionucleotide bone imaging; or (3) elevated prostate specific antigen (PSA). Treatment cycles consisted of docetaxel 60 mg/m2 IV on day 1 and erlotinib 150 mg PO days 1–21. Patients with responding or stable disease after 9 cycles were eligible to continue on erlotinib alone as maintenance therapy.

Results

Characteristics of 22 patients enrolled included: median age 73.5 years (range, 65–80); median Karnofsky Performance Status 90 (range 70–100); median hemoglobin 12.1 g/dl (range, 10.0–14.3); median PSA 218.3 ng/ml (range, 9–5754). A median of 6 treatment cycles were delivered per patient (range 1–17). No objective responses were observed in 8 patients with measurable lesions (0%, 95% CI 0–31%). Bone scan improvement and PSA decline was seen in 1 patient (5%, 95% CI 0.1–25%). Five of 22 patients experienced ≥ 50 % decline in PSA (23%, 95% CI 8–45%). Hematologic toxicity included grade 3 neutropenia in 9 patients and neutropenic fever in 2 patients. Common non-hematologic toxicities (≥ grade 3) included fatigue, anorexia, and diarrhea.

Conclusion

Docetaxel/erlotinib can be delivered safely in elderly patients with AIPC. Anti-cancer disease activity appears generally comparable to docetaxel when used as monotherapy. Hematologic and non-hematologic toxicity may be increased over docetaxel monotherapy. Prospective randomized studies would be required to determine if the toxicity of docetaxel and erlotinib justifies its use in this setting.